Keros Therapeutics (KROS) Cash from Operations (2019 - 2025)
Keros Therapeutics' (KROS) quarterly Cash from Operations came in at 27292000.0 in Q4 2025, up 40.68% YoY from 19400073.17 in Q4 2024, and down 940.01% on a QoQ basis from 3249000.0 in Q3 2025.
Keros Therapeutics (KROS) Cash from Operations (2019 - 2025) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Cash from Operations data on file, last reported at 27292000.0 in Q4 2025.
- Quarterly Cash from Operations rose 40.68% year-over-year to 27292000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 107505000.0 (up 166.83% YoY) and the FY2025 annual result came in at 107505000.0, up 166.83% from the prior year.
- Cash from Operations slipped to 27292000.0 in Q4 2025, from 3249000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 161171000.0 in Q1 2025 to a low of 46008000.0 in Q4 2024.
- A 5-year average of 15504100.0 and a median of 25030500.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations plunged 2299.09% — and 2025, when it jumped 461.69%.
- Tracing KROS's Cash from Operations over 5 years: stood at 19565000.0 in 2021, then slipped by 9.6% to 21443000.0 in 2022, then fell by 18.73% to 25459000.0 in 2023, then sank by 80.71% to 46008000.0 in 2024, then surged by 40.68% to 27292000.0 in 2025.
- The last three Cash from Operations figures came in at 27292000.0 (Q4 2025), 3249000.0 (Q3 2025), and 29623000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -27.29 Mn |
| Dec 31, 2025 | -27.29 Mn |
| Sep 30, 2025 | 3.25 Mn |
| Sep 30, 2025 | 3.25 Mn |
| Jun 30, 2025 | -29.62 Mn |
| Jun 30, 2025 | -29.62 Mn |
| Mar 31, 2025 | 161.17 Mn |
| Mar 31, 2025 | 161.17 Mn |
| Dec 31, 2024 | -46.01 Mn |
| Dec 31, 2024 | -46.01 Mn |
| Sep 30, 2024 | -30.50 Mn |
| Sep 30, 2024 | -30.50 Mn |
| Jun 30, 2024 | -39.80 Mn |
| Jun 30, 2024 | -39.80 Mn |
| Mar 31, 2024 | -44.56 Mn |
| Mar 31, 2024 | -44.56 Mn |
| Dec 31, 2023 | -25.46 Mn |
| Dec 31, 2023 | -25.46 Mn |
| Sep 30, 2023 | -33.98 Mn |
| Sep 30, 2023 | -33.98 Mn |